Nonaqueous fluorinated drug delivery vehicle suspensions
Patent 5173298 Issued on December 22, 1992. Estimated Expiration Date: 
September 27, 2010. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
September 27, 2010. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3911138 Perfluoro polycyclic compounds for use as synthetic blood and perfusion media Ocular system made of bioerodible esters having linear ether Use of perfluorocarbons as wound treatment Extraocular method of treating the eye with liquid perfluorocarbons Ophthalmic treatment by topical administration of cyclosporin Drug delivery system Drug delivery system Patent #: 4882150 InventorApplicationNo. 588697 filed on 09/27/1990US Classes:424/427, Ocular424/78.03, Skin cosmetic coating424/78.04, Ophthalmic preparation424/78.33, Maleic anhydride monomer424/423, Surgical implant or material424/426, Errodable, resorbable, or dissolving424/428, Bioerrodable, resorbable, or dissolving424/434, Mucosal (e.g., nasal, etc.)424/435, Mouth424/499, Contains proteins or derivative or polysaccharides or derivative424/501, Contains solid synthetic resin514/912, OPHTHALMIC514/963, Microcapsule-sustained or differential release514/965, Discrete particles in supporting matrix523/122Composition having ingredient providing biocidal or biostatic protection thereto or process of preparingExaminersPrimary: Page, Thurman K.Assistant: Webman, E. J. Attorney, Agent or FirmForeign Patent References
International ClassesA61K 009/14A61K 047/34 A61K 047/06 A61K 047/32 AbstractNonaqueous pharmaceutical compositions for use in aqueous physiological systems are disclosed comprising drug delivery vehicles suspended in nonaqueous perfluorocarbon or fluorinated silicone liquid carriers. The suspended drug delivery vehicles may be water labile or water stable and incorporate therapeutic or diagnostic compounds which remain stable and pharmaceutically effective for extended periods. The pharmaceutical compositions possess extended shelf-lives and do not leach the incorporated therapeutic or diagnostic compounds into the liquid carriers making them well suited for multi-dose packaging and administration.Field of SearchOcularBioerrodable, resorbable, or dissolving Mucosal (e.g., nasal, etc.) IUD or ring Otic Depot, pellet, matrix, or suppository Surgical implant or material Mouth Implant or insert Errodable, resorbable, or dissolving Contact lens Tampon Diffusion barrier is matrix Membrane or diffusion barrier Vaginal, urethral, uterine Anal, rectal (e.g., suppositories, etc.) Matrices Natural gums, resin or latex Synthetic polymer Acrylic acid and derivatives Polysaccharides (e.g., cellulose, etc.) Containing natural gums/resins Ethyl cellulose Cellulose derivatives Containing waxes, higher fatty acids, higher fatty alcohols, or derivatives thereof Contains waxes, higher fatty acids, higher fatty alcohols Contains proteins or derivative or polysaccharides or derivative Containing polysaccharides (e.g., sugars) Contains natural gums and resins Containing solid synthetic polymers Gelatin Containing proteins and derivatives Coated (e.g., microcapsules) Particulate form (e.g., powders, granules, beads, microcapsules, and pellets) Contains solid synthetic resin OPHTHALMIC Glaucoma Inflammation Wetting agent Microcapsule-sustained or differential release SUSTAINED OR DIFFERENTIAL RELEASE TYPE Discrete particles in supporting matrix Composition having ingredient providing biocidal or biostatic protection thereto or process of preparing | |
